Immuron Limited IMC
ASX · Australia · Health Technology
AUD 0.04000.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S
Immuron (NASDAQ:IMRN) has secured exclusive U. S.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26. The overall U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence). Immuron is targeting a subset of this market with PROIBS®. PROIBS® is a medical device used for abdominal pai
MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectationsIn February 2026 at the time the Company announced a Strategic Reset, 2H FY26 and FY26 Net Sales were projected to both exceed the prior comparative period (pcp) and Net Sales and Net Profit were all projected to exceed pcp. Immuron has exceeded sales projections with second half growth of
MIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) applicationIND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MEL
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing ...
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp)YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp)Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, QuebecYTD Mar 2026 sales AUD$0.1 mi
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's ...
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7418301 C
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now active MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limit
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.